Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

CEVEC and VPM Sign Exclusive License Agreement

Published: Friday, January 04, 2013
Last Updated: Friday, January 04, 2013
Bookmark and Share
Agreement on the clinical development of a novel human CMV vaccine.

CEVEC Pharmaceuticals and VPM - Vakzine Projekt Management GmbH, have announced the signing of an exclusive license agreement on VPM’s proprietary human CMV dense body technology.

CAP® Technology is based on an immortalized human cell line for vaccine and protein production developed by CEVEC for industrial use.

The serum-free suspension culture of this proprietary cell line allows for high virus yields for a broad variety of human pathogenic viruses. CAP® cells are uniquely suited to produce vaccines against challenging viral targets like human CMV.

The non-infectious dense bodies are considered to be one of the most promising new CMV vaccine approaches since they result in efficient and long-lasting immunity.

The CMV dense body project is foreseen to enter clinical development within the next 18 months.

CEVEC receives exclusive word-wide development and commercialization rights from VPM and VPM will substantially contribute by taking over development project management services for the project.

The inventor of the CMV dense body technology, Prof. Dr. Plachter, an internationally reputed CMV expert, actively supports in the project as leading scientific expert.

“With VPM we are teaming up with a very reputed development partner in the field of state-of-the art vaccines for current high-medical need diseases like human CMV. We’re very pleased that VPM and CEVEC are combining our CAP® suspension cells as the enabling production platform with VPMs unique dense body technology. I’m convinced that the dense body technology and CAP® are a perfect match and the combined efforts will substantially shorten the timeline to enter clinical phases,” stated Wolfgang Kintzel, CEO at CEVEC.

"This project shows a scientific and commercial potential untapped in the field of currently pursued viral vaccine targets," Dr. Rainer Lichtenberger, CFO/COO at CEVEC complements.

“It is a great success story in translational research for VPM and Helmholtz Centre for Infection Research that we were able to bring this early stage vaccine project from academia to industry. With the out-licensing of the CMV dense body project to CEVEC, VPM could again demonstrate that its translational business model is instrumental in developing promising vaccine candidates to a stage of maturity where they can envisage a full pharma development. Cooperating with Cevec will help this potentially live-saving vaccine to tap its full potential”, added Dr. Bernd Eisele CEO of VPM.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Completion of a “First in Human” Clinical Phase I Study Using CAP® Cells
Consortium reported safe completion of clinical study with recombinant human Alkaline Phosphatase (hRESCAP®).
Tuesday, November 05, 2013
CEVEC Signs License Agreement with Yuhan of South Korea
License will enable Yuhan to utilize CEVEC’s CAP-T™ and CAP® cell expression systems.
Friday, December 21, 2012
CEVEC Licenses its Proprietary Human Cell Lines to Paragon Bioservices
Paragon Bioservices to perform process development for the contract manufacturing of recombinant proteins and antibodies.
Friday, August 03, 2012
CEVEC Raises €6M to Grow CAP® Technology Based Protein and Vaccine Business
CEVEC announces closing of €6M financing round.
Tuesday, August 09, 2011
Scientific News
Gene Editing Corrects Sickle Cell Mutation
Researchers demonstrate a potential pathway to developing gene-editing treatments for sickle cell disease.
Sustained SIV Remission Achieved in Monkeys
Experimental treatment boosts monkey immune system to force SIV into sustained remission.
Fighting Cancer with Immune Response
New treatment elicits two-pronged immune response that destroys tumors in mice.
Nanoparticles Offer Promising Platform for Flavivirus Treatment
New nanoparticle effectively vaccinated mice against one dengue strain and could be created to target all four.
Overlooked Molecules Could Revolutionise our Understanding of the Immune System
Researchers have discovered that around one third of all the epitopes displayed for scanning by the immune system are a type known as ‘spliced’ epitopes.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
The Power Of Orthogonality In Assessing The Stability Of Biopharmaceuticals
By utilizing orthogonal techniques, researchers can maximize the secure application of all analytical results generated.
Dysfunction in Neuronal Transport Mechanism Linked to Alzheimer’s
Findings confirm mutation-caused problem but also reveal a new therapeutic target.
New Antibody Therapy Permanently Blocks SIV Infection
An international research team has developed an effective treatment strategy against the HIV-like Simian Immunodeficiency Virus (SIV) in rhesus macaques.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos